Nurix Therapeutics (NRIX) Change in Cash (2019 - 2026)

Nurix Therapeutics (NRIX) has 8 years of Change in Cash data on file, last reported at -$3.5 million in Q2 2026.

• On a quarterly basis, Change in Cash fell 142.07% year-over-year to -$3.5 million in Q2 2026; TTM through May 2026 was -$16.5 million, a 49.25% increase from a year earlier, with the FY2025 full-year figure at $137.0 million, up 147.48% from the prior year.
• Change in Cash for Q2 2026 stood at -$3.5 million, up from -$175.8 million in the prior quarter.
• Over the last five years, Change in Cash for NRIX reached as high as $168.5 million in Q4 2025 and fell as low as -$175.8 million in Q1 2026.
• Historically, Change in Cash has averaged -$674388.9 across 5 years, with a median of -$2.3 million in 2022.
• Across the five-year window, Change in Cash sank 2681.55% in 2023 and jumped 1438.59% in 2025, its largest moves.
• Year by year, Change in Cash stood at $16.9 million in 2022, then fell by 27.16% to $12.3 million in 2023, then dropped by 11.12% to $11.0 million in 2024, then soared by 1438.59% to $168.5 million in 2025, then sank by 102.08% to -$3.5 million in 2026.
• Per Business Quant data, the three most recent Change in Cash figures were -$3.5 million in Q2 2026, -$175.8 million in Q1 2026, and $168.5 million in Q4 2025.